Bladder cancer is the second most common malignancy of the genitourinary tract and fifth most common malignancy overall in the United States.1 The current standard for diagnosis and surveillance of bladder cancer includes a combination of cystoscopy and urine cytology.2 The propensity of bladder cancer for recurrence leads to a need for frequent monitoring, making bladder cancer currently the most expensive per-patient malignancy to treat in the United States.3
These points, along with the discomfort, anxiety, and morbidity of frequent cystoscopy have led to much effort in developing alternative, less-invasive methods for bladder surveillance.4 In this commentary, we suggest that no advancement in noninvasive testing has occurred in recent years capable of altering the current endoscopic surveillance scheme. We further argue that the poor performance, marginal clinical utility, and potential harm of the currently available urine tests make them inadequate for regular clinical use.
Howlader N, Krapcho M, Garshell J, eds. SEER Cancer Statistics Factsheets: Bladder Cancer. National Cancer Institute. Bethesda, MD, 2015. Available at http://seer.cancer.gov/statfacts/html/urinb.html. Accessed August 11, 2015.
Svatek RS, Hollenbeck BK, Holmang S. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014;66:253–262.
van der Aa MN, Steyerberg EW, Sen EF. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int 2008;101:1106–1110.
Lokeshwar VB, Habuchi T, Grossman HB. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):35–63.
Yafi FA, Brimo F, Steinberg J. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015;33:66:e25–31.
Sylvester RJ, van der Meijden A, Witjes JA. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(6 Suppl 1):90–107.
Fleshner NE, Herr HW, Stewart AK. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1996;78:1505–1513.
Dimashkieh H, Wolff DJ, Smith TM. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol 2013;121:591–597.
Bubendorf L, Grilli B, Sauter G. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79–86.
Chen GJ, Amiel GE, Roville K. Cost implication of using Urovysion in surveillance care for noninvasive bladder cancer [abstract]. J Urol 2009;181:Abstract 197.
Fritsche HM, Burger M, Dietmaier W. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 2010;134: 597–603.
Trivedi D, Messing EM. Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. BMC Urol 2009;9:13.
Loo RK, Lieberman SF, Slezak JM. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 2013;88:129–138.
Davis R, Jones JS, Barocas DA. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 2012;188(6 Suppl):2473–2481.
Blick CG, Nazir SA, Mallett S. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int 2012;110:84–94.
Cowan NC, Turney BW, Taylor NJ. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int 2007;99:1363–1370.